Equities Analysts Set Expectations for KYTX FY2025 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at HC Wainwright increased their FY2025 EPS estimates for shares of Kyverna Therapeutics in a research report issued on Monday, November 24th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($3.70) per share for the year, up from their previous forecast of ($3.92). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.95) EPS and FY2026 earnings at ($3.71) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.12.

A number of other brokerages have also issued reports on KYTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday. William Blair began coverage on shares of Kyverna Therapeutics in a report on Wednesday, August 20th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company boosted their price objective on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $7.68 on Wednesday. Kyverna Therapeutics has a one year low of $1.78 and a one year high of $8.45. The firm has a market cap of $336.38 million, a P/E ratio of -2.06 and a beta of 3.79. The stock’s 50-day moving average is $6.77 and its 200-day moving average is $4.53.

Institutional Trading of Kyverna Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYTX. Public Employees Retirement System of Ohio bought a new position in Kyverna Therapeutics during the 3rd quarter worth approximately $28,000. Phoenix Wealth Advisors acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth $32,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth $37,000. Qube Research & Technologies Ltd bought a new position in Kyverna Therapeutics during the second quarter worth $43,000. Finally, Ethic Inc. acquired a new position in Kyverna Therapeutics in the second quarter valued at $56,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.